Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Sarcoma 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 2Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma 1Gastro-enteropancreatic neuroendocrine tumor 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × amino-acid, glucose, and electrolyte solution × Clear all
NCT06441331 2026-05-01

KinLET

ITM Solucin GmbH

Phase 1 Recruiting
20 enrolled
CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT05475210 2024-03-13

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Molecular Targeting Technologies, Inc.

Phase 1 Unknown
9 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡